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In the field of non–ST-segment acute coronary syndromes, the evidence from recent
randomized controlled trials favors early invasive management in high-risk patients. How-
ever, data from the recent ICTUS (Invasive versus Conservative Treatment in Unstable
Coronary Syndromes) trial and from several large “real-world” registries suggest that the
benefit may be modest. In contrast, in the field of ST-segment elevation myocardial
infarction, mechanical reperfusion with primary percutaneous coronary intervention (PCI)
has been shown to be superior to thrombolytic therapy. Therefore, efforts should be directed
to the organization of regional networks aimed at prehospital triage and swift transfer of
patients to dedicated PCI centers with experienced staff and high-volume interventional
operators. (J Am Coll Cardiol 2006;48:1136–8) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.095Cardiology Foundation
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Ilinical practice guidelines (CPGs) describe and define best
linical practice and standards of care based on the available
cientific data from preclinical studies, randomized clinical
rials and registries, and clinicians’ expert judgment. Adher-
nce to CPGs has been clearly shown to improve quality of
are and, ultimately, patient outcome. Clinicians dedicated
o the delivery of optimal care in the field of acute coronary
yndromes (ACS) are faced with two major factors that may
omplicate daily treatment decisions: limited resources and
he rapid evolution of the knowledge database. Acute
oronary syndromes may be the field in clinical cardiology
hat is the fastest moving target, with a myriad of clinical
rials being conducted and completed each year, render-
ng the half-life of CPGs shorter while increasing the need
f timely updates. The study by Kereiakes and Antman is
mportant and relevant because the ACS guidelines of the
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) on ST-segment elevation myocardial
nfarction (STEMI) date back to 2004 (1) and the ACC/
HA guidelines on non-STEMI and unstable angina date
ack to 2002 (2). In the field of non–ST-segment elevation
nSTE)-ACS, Kereiakes and Antman reiterate the impor-
ance of risk stratification for the triage of appropriate
atients to an optimal treatment strategy, as the relative
enefit from early invasive treatment is directly proportional
o patient risk profile. However, from the practicing clini-
ian’s perspective, it is important to determine just what
evel of risk defines the patient group that would benefit
ost from early invasive treatment. Should alternative
pproaches be considered, what is the optimal concomitant
edical treatment, and what are the logistical and financial
onsequences of treatment decisions?
In the ICTUS (Invasive versus Conservative Treatment
n Unstable Coronary Syndromes) trial, we could not
emonstrate an early invasive strategy to be superior to a
elective invasive strategy in 1,200 patients with an elevatedi
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edical therapy after 1 year follow-up (3). The result was
nexpected, and many questions have been raised regarding
ethodology, patient profiles, and external validity of the
tudy. The contention that a non–high-risk patient popu-
ation was included in the ICTUS study, which may explain
he findings, is in contrast with previous publications, the
002 AHA/ACC guidelines, and the 2003 ESC guidelines
hat designate nSTE-ACS patients with an elevated cardiac
roponin as high risk, qualifying such patients for glyco-
rotein IIb/IIIa inhibitor treatment, angiography, and sub-
equent revascularization (4). In fact, the baseline charac-
eristics in our study population are quite comparable to
hose in the FRISC-II (FRagmin and Fast Revascularisa-
ion during Instability in Coronary artery disease II) and
ITA (Randomized Intervention Treatment of Angina)-3
rials, with 15% of patients with diabetes being typical for a
uropean nSTE ACS population (5). We did not show a
ortality benefit, which is in contrast with the 2-year results
f the FRISC-II study (6) and the 5-year results of the
ITA-3 study (7) but confirms the conclusion of the recent
eta-analysis by Mehta et al. (8) of all previous randomized
ontrolled clinical trials. Long-term follow-up in the
CTUS study will show whether the early hazard of
evascularization is offset by a late benefit, as was shown in
he RITA-3 5-year follow-up study (7).
We showed that an early invasive strategy with percuta-
eous coronary intervention (PCI) at a median of 24 h after
andomization is associated with an increase in small PCI-
elated myocardial infarctions. This early hazard was also
hown in the meta-analysis by Mehta et al. (8). Meta-
nalyses of strategy trials in nSTE ACS that were con-
ucted over a 10-year time span should, however, be
nterpreted with caution, not only because treatment has
hanged substantially over time (as Kereiakes and Antman
cknowledge) with the use of clopidogrel, glycoprotein
Ib/IIIa inhibitors, and stents, but also because revascular-
zation rate differs significantly among studies. The in-
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September 19, 2006:1136–8 Updating Clinical Guidelines on ACS and STEMIospital revascularization in the FRISC-II study in the
on-invasive and invasive treatment arms was 9% and 71%,
espectively; in the RITA-3 study it was 10% and 44%; and
n the ICTUS study 40% and 76%. Moreover, the revascu-
arization rate at 1 and 2 years in the invasive treatment arm
f the RITA-3 study, for example, is nearly identical to the
evascularization rate in the non-invasive treatment arm in
he ICTUS study, yet they are categorized in separate
ategories in the meta-analysis. With optimized medical
reatment and revascularization rate at 1 year around 55% to
0%, an early invasive treatment may not be necessary for all
STE ACS patients with a positive cardiac troponin.
ndeed, a sub-analysis of the FRISC-II study suggested that
he combination of a positive troponin and ST-segment
hanges on the electrocardiogram identifies the patients that
erived the most benefit from early invasive treatment (9).
lthough the data from randomized controlled clinical trials
ome from highly selected patient populations, as we know,
ata from large “real world” registries regarding invasive or
on-invasive practice patterns in nSTE ACS are conflicting
nd not all reassuring. A consistent finding has been a
azard associated with invasive management, as shown in
everal large-scale registries (from the OASIS [Organiza-
ion to Assess Strategies for Ischaemic Syndromes] and
RACE [Global Registry of Acute Coronary Events]
nvestigators) that reported on clinical practice from centers
round the world in which hospitals with catheterization
acilities did not show better outcomes for ACS patients
han did hospitals without such facilities (10,11). Moreover,
recent analysis from a large Medicare database has shown
hat a high “area level invasive treatment intensity” did not
rovide a clinical benefit over lower invasive treatment
ntensity when beta-blocker treatment intensity in appro-
riate patients was high (12).
In contrast to the field of nSTE ACS, rapid mechanical
eperfusion in patients with STEMI has been clearly and
onsistently shown to be superior to thrombolytic therapy,
rovided that the procedure is performed swiftly and in
igh-volume centers by experienced operators (13,14).
ereiakes and Antman justly summarize the arguments for
he establishment of “ACS centers of excellence” that may
unction as the nucleus of a hub-and-spoke regional care
etwork dedicated to the timely triage, transfer, and treat-
ent of STEMI patients. Such networks have been shown
Abbreviations and Acronyms
ACC  American College of Cardiology
ACS  acute coronary syndrome
AHA  American Heart Association
CPG  clinical practice guideline
nSTE  non–ST-segment elevation
PCI  percutaneous coronary intervention
STEMI  ST-elevation myocardial infarctiono be effective in Europe in reducing door-to-needle timend symptoms-to-reperfusion time and, consequently, in
educing mortality.
In summary, the greater truth might be that in view of
imited resources for the care of ACS patients, practicing
ardiologists should follow CPGs as much as possible,
rganize care in regional collaborations, and optimize the
elivery of timely mechanical reperfusion for all eligible
TEMI patients. The benefit from early invasive treatment
n nSTE ACS patients is dependent on risk profile, and
ith the application of more effective medical treatment, the
enefit may be modest for non-high-risk patients. More-
ver, clinicians should be aware of the early risk associated
ith early revascularization and should verify whether the
omplication rate associated with revascularization in nSTE
CS patients in their own practice mirrors the complication
ate in the centers in which the randomized strategy trials
ere conducted. In this rapidly moving field, future studies
ill demonstrate what level of risk beyond an elevated
ardiac troponin qualifies nSTE ACS patients for early
nvasive treatment and what concomitant medical treatment
ill ensure best medical practice.
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